

# How should I measure this? An FDA perspective on the Bioanalytical Method Validation (BMV)

**June 17, 2019 - 10:00 a.m. to 2:00 p.m. Eastern**

10:00 a.m.	SBIA Opening	Small Business and Industry Assistance (SBIA)   Center for Drug Evaluation and Research (CDER)   FDA
10:05	The Finalized Bioanalytical Method Validation Guidance: What's New for New Drug Applications (NDAs) and Biologics License Applications (BLAs)	<b>Brian Booth, Ph.D.</b> <i>Deputy Director</i> Division of Clinical Pharmacology V Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) CDER   FDA
10:45	Bioanalytical Method Validation of Abbreviated New Drug Applications (ANDAs) - What the reviewer looks for (Part 1& Part 2)	<b>Leah Falade, Ph.D.</b> <i>Lead Pharmacologist</i> <b>Suman Dandamudi, Ph.D.</b> <i>Staff Fellow</i> Office of Bioequivalence (OB) Office of Generic Drugs (OGD) CDER   FDA
11:25	Break for Lunch	
11:55	Bioanalytical Inspections: Overview and Case Studies	<b>Seongeun (Julia) Cho, Ph.D.</b> <i>Division Director</i> <b>John Kadavil, Ph.D.</b> <i>Deputy Director</i> Division of Generic Drug Bioequivalence and Evaluation Office Study Integrity and Surveillance (OSIS) OTS   CDER   FDA
12:35	Accuracy and Precision in Bioanalysis: Review of Case Studies	<b>Charles Bonapace, Pharm.D.</b> <i>Director</i> <b>Arindam Dasgupta, Ph.D.</b> <i>Deputy Director</i> Division of New Drug Bioequivalence and Evaluation OSIS   OTS   CDER   FDA
1:15	Break	
1:25	Panel Discussion and Q&A	Brian Booth, Ph.D. Charles Bonapace, Pharm.D. Seongeun (Julia) Cho, Ph.D. Suman Dandamudi, Ph.D. Arindam Dasgupta, Ph.D. Leah Falade, Ph.D. John Kadavil, Ph.D. Sean Kassim, Ph.D.
1:55	SBIA Closing Remarks	Small Business and Industry Assistance (SBIA)